Maria Salazar's MRNA trades
- The latest MRNA trade was a sale on Sep 24, 2026, when MRNA closed at $194.82. It closed at $186.46 on Oct 22, 2026 (-4%).
Price changes use the closing price on each trade date, not the price actually paid, and ignore dividends. Filings report amounts only as ranges, so these figures show direction, not anyone's actual profit.
Maria Salazar reported 3 MRNA transactions in 2 filings with the House Clerk for 2025–2026: 1 purchase and 2 sales of Moderna, Inc., with trade dates from Aug 19, 2026 to Sep 24, 2026. The median gap between trade date and filing date is 21 days, and every trade was reported within 45 days.
- 3
- 1 / 2
- $3K – $45K
- 2026-10-07
MRNA transactions reported by Maria Salazar
| Type | Owner | ||||
|---|---|---|---|---|---|
Moderna, Inc. - Common Stock MRNA | Sale | Self | $1,001 - $15,000 | 2026-10-07 #20035562 | |
Moderna, Inc. - Common Stock MRNA | Sale | Self | $1,001 - $15,000 | 2026-09-09 #20035411 | |
Moderna, Inc. - Common Stock MRNA | Purchase | Self | $1,001 - $15,000 | 2026-09-09 #20035411 |
A row is a disclosure, not an execution record: the filing reports a date, a bracket, and the reported owner, but not the price, share count, or reason. Compare the trade date with the filing date to see how long the transaction stayed private.
How long disclosure took
Days from trade date to filing date for 3 rows. The STOCK Act allows 30 days from notification and no more than 45 days from the trade. A late row is a timing fact, not evidence of wrongdoing.
- 0–15 days
- 1
- 16–30 days
- 2
- 31–45 days
- 0
- Over 45 days
- 0
- Median / longest
- 21d / 21d
What Maria Salazar's MRNA filings don’t tell you
A disclosure row records a trade date, an amount bracket, and who owned the asset. It does not say why the trade was made, whether the position is still held, or anything about the business behind the ticker: revenue trends, margins, balance-sheet risk, or valuation. Those answers are in company filings, not congressional ones.
- Moderna, Inc. financials and filings
Audited SEC figures, what moves MRNA, and primary sources.
To work through a company yourself, use our stock research checklist. Members get the full version of that work: one sourced investment call a month, with the numbers and the risks that would change the view.
Members-only research
What members are reading this month
- NVIDIA’s growth has a financing bill
Sales up about 18% on the prior quarter, receivables up about 55%, supply commitments at $279 billion. What NVIDIA’s financing bill means for the price you pay.
- Citadel bought the AI fire sale. The seller had run out of time.
Up 439% in the first half, down about 67% in July: how an AI hedge fund ended up selling a roughly $16 billion stock book to Citadel at a discount.
The thesis, the numbers behind it, and what would break it. Full access is $39 a month.
Read the full researchMore tickers reported by Maria Salazar
Maria Salazar and MRNA: questions
Did Maria Salazar buy or sell MRNA?
House Clerk filings for 2025 and 2026 show 1 purchase and 2 sales of Moderna, Inc. (MRNA) reported by Maria Salazar, between 2026-08-19 and 2026-09-24. Reported owner: Self.
How much MRNA did Maria Salazar trade?
Filings disclose brackets, not exact values. Summing the low and high ends of each bracket gives $3K – $45K across 3 transactions. Yield Theory does not estimate share counts, prices, or gains from these ranges.
When was the last MRNA filing by Maria Salazar?
The most recent filing that includes a MRNA trade was filed on 2026-10-07. New filings appear in the House Clerk index and are picked up when the dataset is refreshed.
Yield Theory is not affiliated with any elected official or with Moderna, Inc.. Rows are parsed from public House Clerk periodic transaction reports; amounts are reported brackets and filings can be amended. This page is educational and is not investment advice.
Don’t copy the filing. Read the thesis.
Maria Salazar MRNA disclosures are delayed, ranged, and often a spouse. Members get the monthly call that treats those rows as one input, then names catalysts, risks, and what would change the view. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included